Press Releases

  • TAKEDA CANADA LAUNCHES YOURVANTAGE™ PATIENT SUPPORT PROGRAM FOR MYELOMA PATIENTS PRESCRIBED NINLARO™

    2017.02.03

    Canadians prescribed NINLARO™ will now benefit from personalized support OAKVILLE, Ontario – February 1, 2017 – Takeda Canada Inc. is pleased to support multiple myeloma patients prescribed NINLARO™ (ixazomib) with access to YOURVANTAGE™, a personalized treatment assistance program. In August 2016, Health Canada approved NINLARO™ in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.i NINLARO™ is the first and only oral proteasome inhibitor that provides a needed option for patients managing a devastating, rare, relapsing and incurable...
 

Takeda Pharma